By Greg Roumeliotis
(Reuters) - Valeant Pharmaceuticals International Inc plans to raise its bid for Salix Pharmaceuticals Ltd close to $170 per share, a person familiar with matter told Reuters.
Canada's Valeant is hoping to end a bidding war with Endo International Plc to acquire the bowel drug maker Salix.
Valeant, which last month agreed to buy Salix for $158 per share, or about $10 billion, aims to team up with Ackman's Pershing Square Capital Management and other top shareholders to raise its bid, the source said.
The New York Times earlier reported Valeant's plan to raise its bid to above $160 per share. (http://nyti.ms/1BCpFBp)
Endo International earlier this week offered to buy Salix for $175 per share, or about $11 billion, in cash and stock.
(Reporting by Greg Roumeliotis in New York; Additional reporting by Natalie Grover; Editing by Sriraj Kalluvila and Ken Wills)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app